Prescribing information


▼Beovu® (brolucizumab) is indicated in adults for the treatment of neovascular (wet) AMD.1,2

Two randomised, multicentre, double-masked, active-controlled Phase lll studies.

HAWK and HARRIER: prospective head-to-head trials with q12w intervals immediately after loading in eligible patients*3

Diagram showing the treatment schedule for Beovu and aflibercept in the HAWK and HARRIER trials

  • Primary endpoint: Change in BCVA from baseline to Week 48, measured by ETDRS letter score4
  • Disease activity assessments (DAAs): Anatomical and functional parameters used to determine if patients were eligible for and remained on q12w interval4

Select baseline characteristics

  • Simple mean age: 76 years5
  • Simple mean VA: 61 letters read; comparable between treatment arms5
  • Baseline ocular characteristics for study eye were well balanced across treatment arms§5
  • 73% of patients with unilateral wet AMD4
  • 93% of patients were diagnosed ≤3 months prior to study entry4

Block of text with the words 'Beovu studied in 1,088 patients across centres worldwide3'


Image of the HAWK and HARRIER summary document


Download a handy one-page summary document on HAWK and HARRIER





VA is used to describe BCVA as identified in study protocol.
*Patients were eligible for a q12w interval if no disease activity was observed at Weeks 16 and 20.3
Beovu arms in HAWK: 3 mg (n=358), 6 mg (n=360); in HARRIER: 6 mg (n=370).3,4 HARRIER, confirmatory analysis in HAWK only (1-sided p values for superiority of Beovu).3 The 3 mg dosage is not licensed for use. The recommended dose is 6 mg brolucizumab (0.05 ml solution). Please refer to the SmPC for further information.
Comprehensive DAA criteria at Week 16: Decrease in VA of ≥5 letters compared with baseline; decrease in VA of ≥3 letters and CST increase ≥75 µm compared with Week 12; decrease in VA of ≥5 letters due to wet AMD disease activity compared with Week 12; new or worse IRF/IRC compared with Week 12. DAA criteria at Weeks 20, 32 and 44: Decrease in VA of ≥5 letters due to nAMD activity compared with Week 12.3,5
§Baseline characteristics include VA (letters read), CST-total, presence of fluid (IRF, SRF, sub-RPE), type of CNV and area associated with CNV lesion3,4

AMD, age-related macular degeneration; BCVA, best corrected visual acuity; CNV, choroidal neovascularisation; CST, central subfield thickness; DAA, disease activity assessment; ETDRS, Early Treatment Diabetic Retinopathy Study; IRC, intraretinal cysts; IRF, intraretinal fluid; nAMD, neovascular age-related macular degeneration; q8w, once every 8 weeks, q12w, once every 12 weeks; RPE, retinal pigment epithelium; SRF, subretinal fluid; VA, visual acuity.


  1. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Great Britain, April 2022.
  2. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Northern Ireland, March 2022.
  3. Dugel PU, et al. Ophthalmology 2020;127:72–84.
  4. Novartis data on file. BRODOF20-002 Core Data Sheet; 2019.
  5. Dugel PU, et al. Ophthalmology 2020;127:72–84 (Supplementary information).
Rate this content: 
Average: 3 (8 votes)
UK | May 2022 | 209130

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]